Where I see patients (2)
My reviews
Selected research
-
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
Journal of the National Comprehensive Cancer Network : JNCCN
-
Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma.
Cancer drug resistance (Alhambra, Calif.)
-
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
The Lancet. Oncology
Clinical trials
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantini...
OS of patients who achieve complete response (CR) and progressive disease (PD) from ipilimumab-nivolumab induction phase will be summarized. The stratified log-rank statistic will be the primary analysis to compare the hypothesis ...
Recruiting
4.9